Gestational Trophoblastic Neoplasia: A Comprehensive Clinical Overview

Definition and Subtypes

Gestational trophoblastic neoplasia (GTN) represents the malignant spectrum of gestational trophoblastic disease, with cure rates approaching 100% for low-risk disease and >90% for high-risk disease when managed appropriately 1. GTN encompasses four distinct malignant entities:

Invasive mole (15% of GTD): Extension of hydatidiform mole into myometrium, with 15% metastasizing to lung or vagina
Choriocarcinoma (5% of GTD): Highly vascular malignant epithelial tumor arising from villous trophoblast, characterized by absence of chorionic villi, hemorrhage, and necrosis
Placental site trophoblastic tumor (PSTT) (~1% of GTN): Arises from interstitial trophoblast at implantation site, typically presents months to years after antecedent pregnancy
Epithelioid trophoblastic tumor (ETT) (~1% of GTN): Rare variant arising from chorionic-type intermediate trophoblast, typically presents years after term delivery 1

The benign precursor, hydatidiform mole (HM), comprises 80% of all GTD and transforms to GTN in 15-20% of complete moles but only 1-5% of partial moles 1.

Epidemiology

The incidence of GTD in the United States is approximately 1 in 1,000 pregnancies 1. Historical data shows higher incidence in Asia compared to Europe and North America, attributed to varying diagnostic criteria, reporting practices, and dietary factors 1. PSTT and ETT are exceptionally rare, occurring in approximately 1 in 100,000 pregnancies 1.

Diagnostic Criteria for GTN

GTN is diagnosed following hydatidiform mole evacuation using the FIGO 2000 criteria 2, 3:

Four or more plateaued hCG concentrations over 3 weeks (days 1,7,14,21)
Rise in hCG for three consecutive weekly measurements over at least 2 weeks (days 1,7,14)
Histologic diagnosis of choriocarcinoma or PSTT/ETT

Important caveat: The previously used criterion of "elevated but falling hCG 6 or more months after molar evacuation" is no longer recommended by many centers 3.

For non-molar pregnancies, GTN is diagnosed when hCG remains elevated or rises after any pregnancy event, combined with appropriate imaging findings or histologic confirmation 1.

FIGO Staging and Risk Scoring

FIGO Anatomic Staging 2:

Stage I: Disease confined to uterus
Stage II: GTN extends outside uterus but limited to genital structures
Stage III: Lung metastases with or without genital tract involvement
Stage IV: All other metastatic sites (liver, brain, kidney, spleen, gastrointestinal tract)

FIGO/WHO Prognostic Risk Score 2:

Risk stratification is determined by summing points across seven factors:

Factor	0 points	1 point	2 points	4 points
Age	<40 years	≥40 years	—	—
Antecedent pregnancy	Mole	Abortion	Term birth	—
Interval (months)	<4	4 to <7	7 to <13	≥13
Pretreatment hCG (IU/L)	<10³	10³ to <10⁴	10⁴ to <10⁵	≥10⁵
Largest tumor size (cm)	<3	3 to <5	≥5	—
Site of metastases	Lung	Spleen, kidney	Gastrointestinal	Liver, brain
Number of metastases	—	1-4	5-8	>8

Risk classification:

Low-risk GTN: FIGO score 0-6
High-risk GTN: FIGO score ≥7 OR Stage IV disease (regardless of score)
Ultra-high-risk GTN: Liver and/or brain metastases, particularly if co-occurring 1

Critical note: The FIGO scoring system is not applicable to PSTT/ETT, which require different prognostic assessment 4.

Treatment Protocols

Low-Risk GTN (FIGO Score 0-6)

First-line treatment consists of single-agent chemotherapy, with methotrexate/folinic acid (MTX/FA) preferred in most European centers due to lower toxicity, while actinomycin-D shows higher primary response rates but greater toxicity 4.

Primary treatment options:

Methotrexate with folinic acid rescue: Intramuscular administration alternating daily for 1 week followed by 6 rest days 2
Actinomycin-D: Intravenous administration every 2 weeks, with complete response rates of 70-94% 5

A randomized phase III trial showed complete response rates of 88% for MTX/FA versus 79% for actinomycin-D, with 100% overall survival for both regimens 5. Treatment continues until hCG normalizes, then for an additional 6 consecutive weeks of consolidation therapy 2, 4.

Management of resistant disease:

If resistance develops to first single agent, switch to the alternative single agent (complete response to second-line actinomycin-D: 75-76%) 1
If resistance to sequential single agents occurs, transition to multiagent chemotherapy with EMA/CO 1
Alternative option: Second curettage can cure 40% of patients with low-risk GTN, independent of endometrial thickness 5
Hysterectomy is appropriate for women with completed families and disease confined to uterus 4, 5

Cure rates approach 100% for low-risk GTN, even when first-line therapy fails 1, 4.

High-Risk GTN (FIGO Score ≥7 or Stage IV)

EMA/CO (etoposide, methotrexate, actinomycin-D alternating with cyclophosphamide and vincristine) is the standard first-line multiagent regimen for high-risk GTN, with complete response rates of 62-78% and long-term survival rates of 85-94% 1.

Primary chemotherapy protocol:

EMA and CO given on alternate weeks 1
Treatment duration: Continue until hCG normalizes, then 6 additional weeks of consolidation (extended to 8 weeks for patients with liver and/or brain metastases) 4

Ultra-high-risk disease management:

For patients with extremely high hCG (>400,000 IU/L), liver metastases, or brain metastases, consider induction therapy with low-dose etoposide and cisplatin before EMA/CO to reduce early deaths 4
Alternative: EP/EMA (etoposide/cisplatin alternating with etoposide/methotrexate/actinomycin-D) for ultra-high-risk disease, though limited by increased toxicity 1

Management of resistant/recurrent high-risk disease:

Repeat disease workup including imaging 1
Second-line multiagent chemotherapy: EP/EMA or TE/TP (paclitaxel/etoposide alternating with paclitaxel/cisplatin) 4
Surgical resection of isolated chemoresistant foci when feasible 1, 4

Cure rates for high-risk GTN reach approximately 90%, including almost all patients with only lung/vaginal metastases and 70% for Stage IV disease 1.

Follow-Up Recommendations

Post-Molar Pregnancy (No Chemotherapy)

For complete molar pregnancy 2:

If hCG normalizes within 56 days: Follow-up for 6 months from date of uterine evacuation
If hCG does not normalize within 56 days: Follow-up for 6 months from date of hCG normalization
hCG monitoring frequency: At least every 2 weeks until normal 5

For partial molar pregnancy 2:

Follow-up concluded once hCG returns to normal on two samples at least 4 weeks apart
Shorter surveillance reflects lower malignant potential (1-5% vs 15-20% for complete moles)

Important: Women who have not received chemotherapy no longer require hCG measurement after subsequent pregnancy events 2.

Post-Chemotherapy Surveillance

After successful treatment with chemotherapy 4:

Confirm pregnancy is normal by ultrasound when it occurs
Discontinue routine follow-up during pregnancy
Recheck hCG at 6 and 10 weeks after pregnancy to ensure no recurrence or new disease

Long-term monitoring: Continued surveillance is essential given slight excess risk of leukemias with EMA/CO (though overall second cancer risk is not increased) 4.

Fertility Outcomes

Fertility is preserved in 83% of women after chemotherapy, with menopause occurring approximately 3 years earlier after EMA/CO 4. No significant increase in congenital malformations has been observed in subsequent pregnancies 4.

Management of PSTT and ETT

PSTT and ETT require distinct management approaches as they are less chemosensitive than choriocarcinoma and invasive mole 2, 4, 2.

Risk Stratification for PSTT/ETT

The most critical prognostic factor is the interval from last known pregnancy 4:

Favorable prognosis: Interval <4 years from last pregnancy
Poor prognosis: Interval ≥4 years from last pregnancy
Additional adverse factors: Stage IV disease, metastatic disease 6

Treatment Algorithm

Stage I disease presenting within 4 years of last pregnancy 4:

Primary treatment: Hysterectomy with pelvic lymph node sampling
Surgery alone is sufficient for Stage I disease without high-risk factors 6
Fertility-sparing option: Conservative surgery can be considered in highly selected cases, though data is limited (2 of 3 patients in one series achieved successful pregnancy) 6

Metastatic disease or Stage I with interval ≥4 years 4:

Primary treatment: Multiagent chemotherapy with EP/EMA
Consider high-dose chemotherapy for patients presenting beyond 4 years 4
Surgery for isolated chemoresistant foci when feasible 4

Outcomes for PSTT/ETT

Stage I PSTT has favorable prognosis with surgery alone, while advanced-stage disease remains challenging 6. In one series of 58 PSTT patients, 49 had Stage I disease with excellent outcomes regardless of whether chemotherapy was added to surgery (no significant difference in overall survival, p=0.251) 6. However, Stage IV disease and metastatic disease are the most critical independent predictors of adverse outcomes 6.

The cure rates for PSTT/ETT remain lower than for choriocarcinoma and invasive mole, emphasizing the importance of early diagnosis and appropriate surgical management 7.

Critical Practice Points

Imaging Requirements

Initial staging workup 5, 3:

Pelvic transvaginal Doppler ultrasound
Chest X-ray
If pulmonary metastases ≥1 cm on chest X-ray or hCG >400,000 IU/L: Add chest CT and brain MRI with contrast
Consider CT and/or MRI of abdomen/pelvis for high-risk features

Residual masses after chemotherapy do not predict recurrence and do not require surgical excision 4.

Centralization of Care

Management of GTN is optimized by centralization of care, pathology review, and hCG monitoring at specialized centers 4. This is particularly critical for high-risk disease: patients with high-risk GTN treated initially at tertiary referral centers had cure rates of 89% versus 47% for those treated locally 8.

Common Pitfalls

Avoid multiple curettages: Can cause endometrial scarring without preventing need for chemotherapy 4
Do not use FIGO scoring for PSTT/ETT: These tumors require different prognostic assessment based on interval from pregnancy and stage 4
Ensure adequate MTX dosing: Underdosed MTX regimens show inferior response rates compared to actinomycin-D 5
Recognize ultra-high-risk features early: Liver/brain metastases or extremely elevated hCG require induction therapy to prevent early deaths 4

Have a follow-up question?